Overview
Dr. Ardalan's clinical interests are in juvenile myositis, lupus, and scleroderma and he is co-director of the Duke Children's Myositis Center. He also co-leads the Duke Pediatric Lupus Clinic. Dr. Ardalan's research interests encompass health-related quality of life, patient-reported outcomes, mental health, psychological stress, adverse childhood experiences, cardiovascular health and outcomes research, psychometrics, and qualitative/mixed methods research. His most recent work, funded by the Rheumatology Research Foundation Investigator Award, focuses on the relationships between psychological stress, inflammation, and cardiovascular health in juvenile lupus and dermatomyositis.
Current Appointments & Affiliations
Assistant Professor of Pediatrics
·
2021 - Present
Pediatrics, Rheumatology,
Pediatrics
Recent Publications
Sex Differences in PROMIS Pediatric Depressive Symptoms, Anxiety, and Psychological Stress Among Children and Adolescents Living With Pediatric Rheumatic Diseases.
Journal Article J Rheumatol · March 1, 2026 OBJECTIVE: Children and adolescents living with juvenile idiopathic arthritis (JIA) and childhood-onset systemic lupus erythematosus (cSLE) frequently experience mental health comorbidities. This study evaluated sex differences in symptoms of depression, a ... Full text Link to item CiteTreatment outcomes in 63 cases of juvenile dermatomyositis-associated calcinosis.
Conference Clin Exp Rheumatol · February 2026 OBJECTIVES: We performed a multi-institutional retrospective review of patients treated for juvenile dermatomyositis (JDM)-associated calcinosis to analyse the association between treatment outcomes and patient, disease, and treatment characteristics. METH ... Full text Link to item CiteShared governance of international myositis networks.
Journal Article Clin Exp Rheumatol · February 2026 Full text Link to item CiteRecent Grants
Teams Engaged in Accessible Mental Health Interventions for Lupus Erythematosus and Dermatomyositis Stress
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2025 - 2030A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Subjects with Active Idiopathic Inflammatory Myopathy or A
Clinical TrialPrincipal Investigator · Awarded by Cabaletta Bio, Inc. · 2025 - 2028Using Bioengineered Human Muscle to Develop Treatments for Juvenile Dermatomyositis
ResearchCollaborator · Awarded by Hartwell Foundation · 2025 - 2028View All Grants
Education
University of Virginia, School of Medicine ·
2009
M.D.